Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 5, 2008, Pages 521-527

  Fukuoka, N ^a   Aibiki, M ^b  

^a KAGAWA UNIVERSITY HOSPITAL   (Japan)

^b EHIME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute renal dysfunction; Arbekacin; Clearance; Critically ill patient; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; HABEKACIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RECOMMENDED DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CREATININE; CRITICAL ILLNESS; DATA INTERPRETATION, STATISTICAL; DIBEKACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; KIDNEY FAILURE, ACUTE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; TISSUE DISTRIBUTION;

EID: 52049118336     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00947.x     Document Type: Article

References (20)

1. Kak V, You I, Zervos MJ, Kariyama R, Kumon H, Chow JW (2000) In-vitro synergistic activity of the combination of ampicillin and arbekacin against vancomycin- and high-level gentamicin-resistant Enterococcus faecium with the aph(2″)-Id gene. Diagnostic Microbiology and Infectious Disease, 37, 297 299.
2. Ristuccia AM, Cunha BA (1985) An overview of amikacin. Therapeutic Drug Monitoring, 7, 12 25.
3. Nishizawa K, Ito J, Sugaya K, Nakajima M, Hirano M, Kimura A, Henmi H (1995) Pharmacokinetics of AMK, ABK, VCM in patients with burns. Research in TDM, 12, 165 166 (Abstract in English).
4. Paepe PD, Belpaire FM, Buylaert WA (2002) Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clinical Pharmacokinetics, 41, 1135 1151.
5. Pinder M, Bellomo R, Lipman J (2002) Pharmacological principle of antibiotic prescription in the critically-ill. Anaesthesia and Intensive Care, 30, 134 144.
6. Aronoff K ed 1999) Drug prescribing in renal failure, 4th edn. Churchill-Livingstone : American College of Physicians, 195 236.
7. Fillastre JP, Leroy A, Humbert G, Moulin B, Bernadet P, Josse S (1987) Pharmacokinetics of habekacin in patients with renal insufficiency. Antimicrobial Agents and Chemotherapy, 31, 575 577.
8. Kumon H, Mizuno A, Nasu Y, Tsugawa M, Kishi M, Ohmori H (1989) Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency. The Japanese Journal of Antibiotics, 37, 200 207.
9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 30, 1631 1641.
10. Papaioannou A, Ray JG, Ferko NC, Clarke JA, Campbell G, Adachi JD (2001) Estimation of creatinine clearance in elderly persons in long-term care facilities. American Journal of Medicine, 111, 569 573.
11. Yamamoto T, Koyama M, Nakagawa K (1986) Phase-one clinical study on ABK. Chemotherapy, 34, 104 116 (Abstract in English).
12. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K (2006) Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 50, 3754 3762.
13. Niemiec PW Jr., Allo MD, Miller CF (1987) Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Archives of Surgery, 122, 207 212.
14. Longley JM, Pittman DG, Newby FD (1991) Altered aminoglycoside volume of distribution in patients with acquired immunodeficiency syndrome. Clinical Pharmacy, 10, 784 786.
15. Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE (1976) Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay. Journal of Infectious Diseases, 134, 323 330.
16. Winston L, Benowitz N (2003) Once-daily dosing of aminoglycosides: how much monitoring is truly required? American Journal of Medicine, 15, 239 240.
17. Bartal C, Danon A, Schlaeffer F et al. (2003) Pharmacokinetic dosing of aminoglycosides: a controlled trial. American Journal of Medicine, 15, 194 198.
18. Xuan D, Lu JF, Nicolau DP, Nightingale CH (2000) Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. International Journal of Antimicrobial Agents, 15, 185 191.
19. Reimann IR, Meiler-Hellmann A, Traut T, Reinhart K, Hoffmann A (2003) Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically-ill patients. Experimental and Toxicologic Pathology, 54, 493 498.
20. Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K (2006) Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 50, 3763 3769.